Pesquisas alternativas:
level theory » legal theory (Expandir a Pesquisa), model theory (Expandir a Pesquisa)
devel ther » novel ther (Expandir a Pesquisa), develop them (Expandir a Pesquisa)
drug doses » drug dose (Expandir a Pesquisa), drug disease (Expandir a Pesquisa)
drug does » drugs does (Expandir a Pesquisa), drug dose (Expandir a Pesquisa), drug de (Expandir a Pesquisa)
level theory » legal theory (Expandir a Pesquisa), model theory (Expandir a Pesquisa)
devel ther » novel ther (Expandir a Pesquisa), develop them (Expandir a Pesquisa)
drug doses » drug dose (Expandir a Pesquisa), drug disease (Expandir a Pesquisa)
drug does » drugs does (Expandir a Pesquisa), drug dose (Expandir a Pesquisa), drug de (Expandir a Pesquisa)
1
“... indicate that the polymer-bound drug does not diffuse into the muscle tissues. We feel that our findings...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
2
“..., this study aimed to evaluate the pharmacokinetic (PK) interactions between these two drugs in healthy males...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
3
Por Guerrero-Orriach, Jose Luis, Escalona Belmonte, Juan Jose, Ramirez Fernandez, Alicia, Ramirez Aliaga, Marta, Rubio Navarro, Manuel, Cruz Mañas, Jose
Publicado no Drug Des Devel Ther (2017)
“... is related to the dose-dependent signal, while the degree of protection is related to the concentration...”Publicado no Drug Des Devel Ther (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
4
Por Wu, Jianhui, Zhao, Ming, Wang, Yuji, Wang, Yaonan, Zhu, Haimei, Zhao, Shurui, Gui, Lin, Zhang, Xiaoyi, Peng, Shiqi
Publicado no Drug Des Devel Ther (2017)
“... S180 mice, and has a minimal effective dose of 2 nmol/kg per day. At 200 nmol/kg per day, HMCEF does...”Publicado no Drug Des Devel Ther (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
5
Por Gahr, Maximilian, Kölle, Markus A, Schönfeldt-Lecuona, Carlos, Lepping, Peter, Freudenmann, Roland W
Publicado em 2011
“... pharmacological profile, including single dosing, predominantly renal excretion, low drug–drug interaction risk...”Publicado em 2011
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
6
Por Shen, Zancong, Gillen, Michael, Tieu, Kathy, Nguyen, Mai, Harmon, Erin, Wilson, David M, Kerr, Bradley, Lee, Caroline A
Publicado no Drug Des Devel Ther (2016)
“... doses, does not have a significant effect on the QT interval in healthy male or female subjects....”Publicado no Drug Des Devel Ther (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
7
“... once daily infusion and does not require dose adjustments for renal or moderate hepatic dysfunction...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
8
Por Mumoli, Laura, Palleria, Caterina, Gasparini, Sara, Citraro, Rita, Labate, Angelo, Ferlazzo, Edoardo, Gambardella, Antonio, De Sarro, Giovambattista, Russo, Emilio
Publicado no Drug Des Devel Ther (2015)
“... requires dose adjustment. BRV does not seem to influence other antiepileptic drug plasma levels. Six...”Publicado no Drug Des Devel Ther (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
9
Por Coppola, Giangennaro, Iapadre, Giulia, Operto, Francesca Felicia, Verrotti, Alberto
Publicado no Drug Des Devel Ther (2017)
“...Currently, a number of novel anticonvulsant drugs, the so-called third generation, are in various...”Publicado no Drug Des Devel Ther (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
10
Por Urbina, Olatz, Ferrández, Olivia, Espona, Mercè, Salas, Esther, Ferrández, Irene, Grau, Santiago
Publicado em 2013
“... with tedizolid when used at the therapeutic dose of 200 mg in Phase I, II, or III clinical trials of up to 3...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
11
Por Blandizzi, Corrado, Viscomi, Giuseppe Claudio, Scarpignato, Carmelo
Publicado no Drug Des Devel Ther (2014)
“... was specifically prepared for the study and formulated as the marketed product. Two doses (200 mg and 400 mg...”Publicado no Drug Des Devel Ther (2014)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
12
Por Hoch, Matthias, Darpo, Borje, Remenova, Tatiana, Stoltz, Randall, Zhou, Meijian, Kaufmann, Priska, Bruderer, Shirin, Dingemanse, Jasper
Publicado no Drug Des Devel Ther (2014)
“... were randomized to receive escalating doses of selexipag (n=91) or placebo/moxifloxacin (n=68...”Publicado no Drug Des Devel Ther (2014)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
13
“... that undergoes primarily renal elimination and does not affect cytochrome P450 enzymes. Assays to quantify...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
14
Por Mok, Chi Chiu
Publicado em 2013
“... for the treatment of rheumatoid arthritis (RA) that does not respond adequately to disease-modifying antirheumatic...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
15
Por Cossu, Maria Vittoria, Cattaneo, Dario, Fucile, Serena, Pellegrino, Paolo, Baldelli, Sara, Cozzi, Valeria, Capetti, Amedeo, Clementi, Emilio
Publicado em 2014
“... and to optimize the dosing of the combination of the drugs isosorbide dinitrate, a nitric oxide donor...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
16
Por Doupis, John
Publicado em 2014
“... reduction, typically ranging from 0.6% to 0.8% depending on baseline levels. In addition...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
17
Por Darkovska-Serafimovska, Marija, Janevik-Ivanovska, Emilija, Djorgoski, Icko, Arsova-Sarafinovska, Zorica, Zdravkovska, Milka, Balkanov, Trajan, Ugresic, Nenad
Publicado no Drug Des Devel Ther (2016)
“... aggregometer. Binding of (99m)Tc-tirofiban to platelets was evaluated. Serum levels of unlabeled (a validated...”Publicado no Drug Des Devel Ther (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
18
Por Guo, Yan, Sun, Juan, Ye, Juan, Ma, Wenyu, Yan, Hualing, Wang, Gang
Publicado no Drug Des Devel Ther (2016)
“...), S. tridactyla Sch. Bip.-derived polysaccharides and flavones low-dose group, and S. tridactyla Sch. Bip.-derived...”Publicado no Drug Des Devel Ther (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
19
Por Amato, Bruno, Compagna, Rita, Rocca, Aldo, Bianco, Tommaso, Milone, Marco, Sivero, Luigi, Vigliotti, Gabriele, Amato, Maurizio, Danzi, Michele, Aprea, Giovanni, Gallelli, Luca, de Franciscis, Stefano, Serra, Raffaele
Publicado no Drug Des Devel Ther (2016)
“... asymptomatic pulmonary embolism (APE). In most cases, these patients are treated with anticoagulant drugs...”Publicado no Drug Des Devel Ther (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
20
Por Aljimaee, Yazeed HM, El-Helw, Abdel-Rahim M, Ahmed, Osama AA, El-Say, Khalid M
Publicado no Drug Des Devel Ther (2015)
“...-pass metabolism, the absolute bioavailability of CVD does not exceed 30%. To overcome these drawbacks...”Publicado no Drug Des Devel Ther (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo